MétaCan
Menu
Back to cohort
Record W3119648922 · doi:10.1101/2021.01.07.21249390

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report

2021· preprint· en· W3119648922 on OpenAlex
Anthony Gordon, Paul Mouncey, Farah Al-Beidh, Kathy Rowan, Alistair Nichol, Yaseen M. Arabi, Djillali Annane, Abi Beane, Wilma van Bentum-Puijk, Lindsay R. Berry, Zahra Bhimani, Marc J. M. Bonten, Charlotte Bradbury, Frank M. Brunkhorst, Adrian Buzgau, Allen Cheng, Michelle A. Detry, Eamon Duffy, Lise J Estcourt, Mark Fitzgerald, Herman Goossens, Rashan Haniffa, Alisa M. Higgins, Thomas Hills, Christopher M. Horvat, François Lamontagne, Patrick R. Lawler, Helen L. Leavis, Kelsey Linstrum, Edward Litton, Elizabeth Lorenzi, John C. Marshall, Florian Mayr, Anna McGlothlin, Shay McGuinness, Bryan J. McVerry, Stephanie K. Montgomery, Susan C. Morpeth, Srinivas Murthy, Katrina Orr, Rachael Parke, Asad E. Patanwala, Ville Pettilä, Emma Rademaker, Marlene Santos, Christina Saunders, Christopher W. Seymour, Manu Shankar‐Hari, Wendy Sligl, Alexis F. Turgeon, Anne Turner, Frank L. van de Veerdonk, Ryan Zarychanski, Cameron Green, Roger Lewis, Derek Angus, Colin McArthur, Scott Berry, Steve Webb, Lennie Derde

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenuemedRxiv · 2021
Typepreprint
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsUniversity of ManitobaUniversité LavalUniversity of AlbertaUniversity Health NetworkUniversity of TorontoUniversity of British ColumbiaUniversité de SherbrookeSt. Michael's Hospital
FundersFP7 HealthNIHR Imperial Biomedical Research CentreHealth Research Council of New ZealandMinderoo FoundationDepartment of Health and Social CareNational Institute for Health and Care ResearchHealth Research BoardMedical Research CouncilBreast Cancer Research FoundationEuropean CommissionSanofiWellcome TrustNational Health and Medical Research Council
KeywordsTocilizumabMedicineInterquartile rangeInternal medicineIntensive care unitOdds ratioRandomized controlled trialDisease

Abstract

fetched live from OpenAlex

Abstract Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours of commencing organ support in an intensive care unit, were randomized to receive either tocilizumab (8mg/kg) or sarilumab (400mg) or standard care (control). The primary outcome was an ordinal scale combining in-hospital mortality (assigned −1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with pre-defined triggers to declare superiority, efficacy, equivalence or futility. Results Tocilizumab and sarilumab both met the pre-defined triggers for efficacy. At the time of full analysis 353 patients had been assigned to tocilizumab, 48 to sarilumab and 402 to control. Median organ support-free days were 10 (interquartile range [IQR] −1, 16), 11 (IQR 0, 16) and 0 (IQR −1, 15) for tocilizumab, sarilumab and control, respectively. Relative to control, median adjusted odds ratios were 1.64 (95% credible intervals [CrI] 1.25, 2.14) for tocilizumab and 1.76 (95%CrI 1.17, 2.91) for sarilumab, yielding >99.9% and 99.5% posterior probabilities of superiority compared with control. Hospital mortality was 28.0% (98/350) for tocilizumab, 22.2% (10/45) for sarilumab and 35.8% (142/397) for control. All secondary outcomes and analyses supported efficacy of these IL-6 receptor antagonists. Conclusions In critically ill patients with Covid-19 receiving organ support in intensive care, treatment with the IL-6 receptor antagonists, tocilizumab and sarilumab, improved outcome, including survival. ( ClinicalTrials.gov number: NCT02735707 )

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.294
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Research integrity
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.293
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.294
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.003
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.407
Teacher spread0.362 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it